Who are Amlodipine/Olmesartan's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amlodipine-olmesartan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Amlodipine/Olmesartan — Competitive Intelligence Brief

Amlodipine/Olmesartan (Amlodipine/Olmesartan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker / Angiotensin II receptor blocker combination. Area: Cardiovascular.

marketed Calcium channel blocker / Angiotensin II receptor blocker combination L-type calcium channels (amlodipine); AT1 angiotensin II receptor (olmesartan) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine/Olmesartan (Amlodipine/Olmesartan) — Radboud University Medical Center. Amlodipine relaxes blood vessels by blocking calcium channels, while olmesartan blocks angiotensin II receptors to reduce vasoconstriction and lower blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amlodipine/Olmesartan TARGET	Amlodipine/Olmesartan	Radboud University Medical Center	marketed	Calcium channel blocker / Angiotensin II receptor blocker combination	L-type calcium channels (amlodipine); AT1 angiotensin II receptor (olmesartan)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker / Angiotensin II receptor blocker combination class)

Radboud University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine/Olmesartan — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-olmesartan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab